Originally published on Thu April 11, 2013 7:04 am
The patent medicines sold in days gone by may, contrary to the name, not have had real government patents. But that didn't stop their makers from claiming the concoctions could cure ailments ranging from indigestion to jaundice and fever.
Now, researchers have put some of these old elixirs and pills in the Henry Ford Museum's large collection of patent medicines to a modern test. They found a mix of potentially harmful metals like lead and mercury along with benign ingredients, including calcium and iron.
Originally published on Fri April 5, 2013 12:57 pm
With one-quarter of adults over age 45 taking cholesterol-lowering statin drugs, it figures that more than a few people would have trouble sticking with the program.
More than a few, actually.
A big new study of statin use in the real world found that 17 percent of patients taking the pills reported side effects, including muscle pain, nausea, and problems with their liver or nervous system.
That's a lot higher than the 5 to 10 percent reported in the randomized controlled trials that provided evidence for regulatory approval of the medicines.
A decision by India's Supreme Court to reject Novartis AG's bid to patent a version of one cancer drug could lead to more exports of cheap medicine from that country to "poor people across the developing world," the BBC writes.
NPR's Julie McCarthy tells our Newscast Desk that the ruling, announced Monday, ends a six-year legal battle that has been closely watched by pharmaceutical firms, humanitarian aid organizations and generic drug manufacturers.
Last year, a new drug called Zaltrap was approved as a kind of last-chance therapy for patients with colorectal cancer. Studies suggested Zaltrap worked almost exactly as well as an existing drug called Avastin. In fact, the main difference between the two drugs seemed to be the price.
"I was rather stunned," Dr. Leonard Saltz, who specializes in colorectal cancer, told me.
Zaltrap costs about $11,000 per month — about twice as much as Avastin, Saltz said.